Type at least 2 characters to search
Why do so many drug discovery breakthroughs fail to reach patients? Trisha Pillay speaks with Christian Nkanga to find out.
The DMTA cycle is the engine of modern pharma R&D. Learn how integrated DMTA workflows reduce early-stage attrition and compress drug discovery timelines.
Explore the critical differences between preclinical vs clinical research, and how closing the translation gap can reduce drug development attrition and improve R&D decision-making.
Explore the biggest drug discovery challenges facing pharma today, from translational gaps to AI integration, and why a new pharma paradigm is needed.
From 2012 through 2024, the FDA only approved 22 drugs for the treatment of psychiatric conditions. Pharma R&D teams must rethink development strategies to unstall drug innovation in psychiatry
Pharmacoinformatics is redefining drug discovery strategy. This analysis covers the AI platforms, molecular design tools, and regulatory frameworks shaping R&D pipelines in 2026.
No result found for
Discover innovative solutions and insights from leading pharmaceutical and life sciences companies driving advances in drug development, biotechnology, healthcare, and scientific innovation.
